MK-677

MK-677 is a non-peptide molecule — meaning it is not an amino acid chain but rather a small organic compound — that selectively agonizes the growth hormone secretagogue receptor (GHS-R, also called the ghrelin receptor). This is the same receptor targeted by injectable GHRPs like Ipamorelin, but MK-677's non-peptide structure gives it oral bioavailability and a dramatically extended half-life of approximately 24 hours. This combination of oral administration and once-daily dosing makes MK-677 the most accessible GH secretagogue for individuals who cannot or will not self-inject. It produces meaningful, measurable elevations in GH and IGF-1 across human clinical trials, with documented effects on body composition, sleep architecture, and bone density. Despite substantial human clinical trial data, MK-677 was never brought to market by its developers (Merck and later Lumos Networks) due to commercial rather than safety reasons. It is currently classified as a research chemical and is widely available without a prescription.

IGF-1 elevation is MK-677's most consistently documented quantitative benefit. Human trials have shown dose-dependent IGF-1 increases of 30–90% above baseline with 10–25 mg daily dosing. IGF-1 elevation drives downstream benefits across muscle protein synthesis, fat metabolism, connective tissue health, and cognitive function. Sleep quality improvement — particularly increased slow-wave (deep) sleep — is one of the most reliably reported effects. Growth hormone is predominantly released during deep sleep, and MK-677's GH elevation appears to both amplify and reflect improved sleep architecture. Users frequently report this as the most immediately noticeable benefit, often within the first week. Body composition improvements emerge gradually over months. Studies in elderly subjects showed significant increases in fat-free mass and reductions in fat mass. Muscle gains are modest and realistic — not comparable to SARMs or steroids — but meaningful in the context of recovery and anti-aging. Bone density improvement has been documented in clinical trials, with particularly notable results in elderly patients. MK-677's ability to preserve bone mineral density makes it potentially valuable for aging populations.

Increased hunger is the most universal and significant side effect. Ghrelin is known as "the hunger hormone," and MK-677's ghrelin receptor agonism produces corresponding appetite stimulation. This makes MK-677 conducive to bulking but actively counterproductive when cutting — caloric control becomes genuinely difficult for many users. Water retention and mild edema — particularly in the hands and feet — are common, especially early in a protocol. This often resolves partially after the first 4–8 weeks as the body adapts to elevated GH and IGF-1. Insulin resistance worsening is a documented pharmacological effect. GH elevation suppresses peripheral insulin sensitivity; users with pre-existing glucose regulation issues or metabolic syndrome should monitor fasting glucose and HbA1c. This is the most clinically significant risk for long-term users. Lethargy and increased sleepiness — particularly if taken in the morning — are reported by many users. Evening dosing mitigates this for most people, converting the sedating effect into improved sleep quality rather than daytime fatigue. Joint pain and carpal tunnel-like symptoms occur in some users, consistent with the known joint effects of GH elevation at higher IGF-1 levels.

Starting dose: 10–15 mg once daily, taken in the evening or at bedtime to capitalize on sleep benefits and convert any sedating effects into improved sleep rather than daytime lethargy. Standard dose: 20–25 mg daily is most commonly used in research protocols and anecdotal experience. The dose-response curve flattens above 25 mg with increasing side effects but diminishing additional GH/IGF-1 benefit. Cycle length: MK-677 is often run in extended cycles of 3–6 months given its mechanism of action and the time required for meaningful body composition change. Some practitioners run it continuously with periodic bloodwork monitoring. Fasting: MK-677 does not require fasting — unlike injectable GHRPs, which require an insulin-free environment for optimal GH release. MK-677 can be taken with food. Monitoring: Periodic fasting glucose and IGF-1 testing is advisable for anyone running MK-677 for more than 8 weeks to monitor insulin sensitivity and confirm therapeutic IGF-1 levels.

United States: MK-677 is not FDA approved as a drug and is not a controlled substance. It is legal to purchase and possess as a research chemical. It has been the subject of FDA warning letters to vendors who make medical claims or sell it explicitly for human consumption. Recent FDA actions: In 2023–2024, the FDA took enforcement action against several peptide and research chemical vendors, with MK-677 named alongside other compounds. The regulatory environment is tightening, and domestic availability may become more restricted. WADA / Sports: MK-677 is prohibited under the WADA code as a GH secretagogue. Athletes in tested sports should not use it.

MK-677 + RAD-140: A popular body composition stack. RAD-140 drives muscle and strength gains; MK-677 adds GH/IGF-1 elevation for recovery, sleep, and connective tissue support. The combination produces synergistic body composition effects while MK-677's anti-catabolic properties complement RAD-140's anabolic activity. MK-677 + LGD-4033: A bulking-focused combination. LGD-4033 delivers strong lean mass gains; MK-677 amplifies the anabolic environment through IGF-1 and improves recovery and sleep during an intense bulking phase. MK-677 + BPC-157: For recovery-focused users, MK-677's systemic GH/IGF-1 elevation combined with BPC-157's targeted tissue repair addresses recovery from multiple angles.

MK-677 — Common Questions